Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

640 (5).png

Litchlab Pioneers Radiopharmaceutical Drug Conjugate (RDC) Innovation: Advancing Precision Oncology

Breakthroughs in the RDC Field & Market TrendsThe global Radiopharmaceutical Drug Conjugate (RDC) sector is witnessing rapid advancements. On March 25, 2025, Kelun-Biotech, a leading Chinese biopharmaceutical company, announced that its radiopharmaceutical...

640 (1).jpg

Litchlab Pioneers Vaccine Delivery Innovation, Driving the Next Era of Global Vaccine Development

Breakthroughs in Global Vaccine R&D: Delivery Systems at the ForefrontIn early 2025, multiple groundbreaking advancements in vaccine development were reported. GlaxoSmithKline (GSK) announced promising Phase II clinical trial results for its mRNA-based sea...

640 (4).png

Litchlab Empowering ADC Drug Delivery—Precision, Efficiency, and Safety

Antibody-drug conjugates (ADCs) have revolutionized oncology by enabling targeted drug delivery to cancer cells while minimizing toxicity to healthy tissues. However, the success of ADCs relies not only on the selection of antibodies and cytotoxic payloads but...

Litchlab Powers ADC Innovation—Advancing Antibody-Drug Conjugate (ADC) Delivery for Precision Oncology

Datroway Wins FDA Approval, Marking a New Breakthrough in ADC TherapeuticsIn January 2025, the U.S. Food and Drug Administration (FDA) officially approved Datroway (datopotamab deruxtecan), an antibody-drug conjugate (ADC) co-developed by AstraZeneca and Daiic...

纳米载体5.jpg

Litchlab: Enabling Global Pharmaceutical Innovation with cGMP-Grade Liposome & LNP Manufacturing

Accelerating the Commercialization of Next-Generation NanomedicineWith the rapid advancements in mRNA vaccines, siRNA therapeutics, gene editing, and cancer immunotherapy, liposomes and lipid nanoparticles (LNPs) have become the cornerstone of modern drug deli...

640 (3).png

Litchlab’s Next-Generation Antibody-Drug Conjugates (ADC): Advancing Precision Oncology Innovative ADC Technology: A New Era in Targeted Cancer Therapy

Antibody-drug conjugates (ADCs) represent a major advancement in modern oncology, combining the target specificity of monoclonal antibodies (mAbs) with highly potent cytotoxic drugs. This approach enables precise tumor cell elimination while minimizing damage ...

上一页 1 2 3 4 5 下一页